.terms_of_service_block{display:block;}.terms_of_service_block.terms_btn_toggle{display:none;}
Symbol | VATE |
Exchange | NYSE |
Major index membership | - |
Current market capitalization | 169.48M |
Trailing 12-month net income | -28.50M |
Trailing 12-month sales revenue | 1.23B |
Current book value per share (BPS) | -12.39 |
Current cash value per share (CPS) | 3.91 |
Annual dividend payout | - |
Annual dividend accrual | - |
Dividend ex-date | Aug 28, 2013 |
Number of full-time employees | 4024 |
Stock with tradable options and short sales | No / Yes |
Last quarter sales surprise | - |
Distance from 20-day simple moving average (SMA20) | 13.31% |
Trailing 12-month price-to-earnings ratio (P/E ratio) | - |
Forward 12-month price-to-earnings ratio (P/E ratio) | - |
Price-to-earnings growth (PEG) | - |
Trailing 12-month price-to-sales ratio (P/S ratio) | 0.14 |
Current price-to-book ratio (P/B ratio) | - |
Current price-to-cash ratio (P/C ratio) | 3.27 |
Trailing 12-month price-to-free-cash-flow ratio (P/FCF ratio) | 13.78 |
Most recent quick ratio | 0.81 |
Most recent current ratio | 0.85 |
Most recent debt-to-equity leverage (D/E ratio) | - |
Most recent long-term-debt-to-equity leverage (LTD/E ratio) | - |
Last quarter earnings-per-share (EPS) surprise | - |
Distance from 50-day simple moving average (SMA50) | 64.38% |
Trailing 12-month earnings-per-share (EPS) | -3.67 |
Forward annual earnings-per-share (EPS) | - |
Forward quarterly earnings-per-share (EPS) | - |
Current earnings-per-share growth (EPSG) | - |
Forward earnings-per-share growth (EPSG) | - |
Long-term current earnings-per-share growth (EPSG) | - |
Long-term past earnings-per-share growth (EPSG) | - |
Long-term past sales revenue growth (SRG) | 14.33% |
Short-term earnings-per-share growth (EPSG) | 31.36% |
Short-term sales revenue growth (SRG) | -16.30% |
Last quarter earnings-per-share growth (EPSG) | -27.65% |
Last quarter sales revenue growth (SRG) | -35.46% |
Distance from 200-day simple moving average (SMA200) | 110.99% |
Insider stock ownership concentration | 60.17% |
Most recent change in insider ownership | 0.87% |
Institutional stock ownership concentration | 21.17% |
Most recent change in institutional ownership | 25.54% |
Trailing 12-month return on assets (ROA) | -2.74% |
Trailing 12-month return on equity (ROE) | - |
Trailing 12-month return on investment (ROI) | -7.15% |
Trailing 12-month gross profit margin (GPM) | 16.73% |
Trailing 12-month operating profit margin (OPM) | 4.00% |
Trailing 12-month net profit margin (NPM) | -2.31% |
Trailing 12-month dividend payout ratio | - |
Earnings date before/after market open/close (BMO/AMC) | Nov 06 AMC |
Additional trade activity | N/A |
Number of outstanding shares | 13.17M |
Number of floating shares | 5.27M |
Number of short-interest shares | 10.43% |
Short interest ratio | 0.87 |
Short interest dollar amount | 0.55M |
Trailing 52-week stock price range | 3.25 - 13.50 |
Distance from 52-week high | -5.33% |
Distance from 52-week low | 293.23% |
Relative strength index (RSI) | 67.77 |
Stock analysts' average recommendation (1=buy to 5=sell) | 1.00 |
Current relative trading volume | 0.15 |
Current average trading volume | 630.12K |
Current stock trading volume | 96,208 |
Most recent weekly stock price performance | 7.58% |
Most recent monthly stock price performance | 163.51% |
Most recent quarterly stock price performance | 213.24% |
Most recent semi-annual stock price performance | 153.57% |
Most recent annual stock price performance | 32.24% |
Most recent year-to-date stock price performance | 158.70% |
Most recent stock market beta | 2.49 |
Current average true range | 1.02 |
Most recent weekly and monthly return volatility | 8.47% 12.74% |
Stock analysts' average target price | 8.49 |
Previous stock price close-of-business | 13.39 |
Current stock price | 12.78 |
Most recent daily stock price performance | -4.56% |
2023-08-21 12:25:00 Monday ET
Steven Shavell presents his economic analysis of law in terms of the economic outcomes of both legal doctrines and institutions. Steven Shavell (2004)
2017-06-09 06:37:00 Friday ET
To complement President Trump's pro-business economic policies such as low taxation, new infrastructure, greater job creation, and technological in
2019-04-01 08:28:00 Monday ET
OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome s
2023-09-21 09:26:00 Thursday ET
Jordi Gali delves into the science of the New Keynesian monetary policy framework with economic output and inflation stabilization. Jordi Gali (2015)
2018-10-17 12:33:00 Wednesday ET
The Trump administration blames China for egregious currency misalignment, but this criticism cannot confirm *currency manipulation* on the part of the Chin
2023-08-07 12:29:00 Monday ET
Oxford macro professor Stephen Nickell and his co-authors delve into the trade-off between inflation and unemployment in the dual mandate of price stability